SCHEMBL21751301

SCHEMBL21751301

Nc1ncc(Br)nc1Cc1c(F)cccc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.37
HTT P42858 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
PPP1CA P62136 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
AR P10275 1/20 0.37
MPO P05164 1/20 0.37
ALDH1A1 P00352 2/20 0.35
RAB9A P51151 1/20 0.35
MAPKAPK2 P49137 1/20 0.34
CYP1A2 P05177 3/20 0.33
CYP3A4 P08684 3/20 0.33
CYP2C9 P11712 3/20 0.33
CYP2C19 P33261 3/20 0.33
PKM P14618 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ATR Q13535 1/20 0.33
ADORA2A P29274 2/20 0.32
ADORA2B P29275 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30800189 1.00 NPC1 (0.37) NPC1HTTL3MBTL1PPP1CASMN1; SMN2
SCHEMBL29281616 0.83 MPO (0.41) NPC1HTTL3MBTL1MPOALDH1A1
SCHEMBL21751294 0.83 ALDH1A1 (0.46) NPC1HTTL3MBTL1ARMPO
SCHEMBL30800166 0.83 ALDH1A1 (0.46) NPC1HTTL3MBTL1ARMPO
SCHEMBL934740 0.75 LTB4R (0.46) MPOMAPKAPK2CYP1A2CYP3A4CYP2C9
Ammonia Solution, Strong SCHEMBL5381714 0.74 MPO (0.35) MPO
SCHEMBL15606358 0.74 CSF1R (0.42)
SCHEMBL28003702 0.73 NPC1 (0.42) NPC1HTTL3MBTL1PPP1CASMN1; SMN2
SCHEMBL21751424 0.71 LTA4H (0.43) SMN1; SMN2TDP1MPOALDH1A1MAPKAPK2
SCHEMBL30800174 0.71 LTA4H (0.43) SMN1; SMN2TDP1MPOALDH1A1MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3981839-B1 COELENTERAZINE ANALOGS FOR USE IN LUCIFERASE-BASED ASSAYS PROMEGA CORP (US) 2025-08-20 EP disclosed
US-20240059697-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2024-02-22 US disclosed
CN-112513188-B Coelenterazine analogs 普洛麦格公司 2024-01-26 CN disclosed
US-11691976-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2023-07-04 US disclosed
US-11691976-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2023-07-04 US disclosed
US-11691976-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2023-07-04 US disclosed
EP-3841173-A1 COELENTERAZINE ANALOGUES Promega Corporation (US) 2021-06-30 EP disclosed
CN-112513188-A Coelenterazine analogs 普洛麦格公司 2021-03-16 CN disclosed
US-20200062766-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2020-02-27 US disclosed
WO-2020041579-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION (US) 2020-02-27 WO disclosed
US-20200062766-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2020-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062766-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 NPC1 1085/4885HTT 2358/4885L3MBTL1 52/4885
US-11691976-B2 Coelenterazine analogues GLB1, SI, TCF7L2 NPC1 1085/4885HTT 2358/4885L3MBTL1 52/4885
US-20240059697-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 NPC1 1085/4885HTT 2358/4885L3MBTL1 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.